Últimas noticias sobre Vital Energy (NYSE:VTLE) Bolsa

Vital Energy

Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.

Vital Energy, Inc. Common Stock, par value $0.01 per share

BofA Securities analyst Joshua Shanker downgraded Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from Buy to Neutral, lowering<a href="https://www.benzinga.com/quote/PGR/analyst-ratings" target="_blank" rel="noreferrer noopener"> the price forecast from $300 to $287.</a>
Shanker noted that while investors have recently shifted into Progressive as a &#8220;defensive&#8221; play amid recession concerns and new U.S. tariffs, it&#8217;s important to recognize that the company may currently be experiencing a cyclical &#8220;margin peak.&#8221;
Although auto insurance is inherently a cyclical business, Progressive has benefited from its defensive positioning in the market.
However, earnings growth is expected to &#8220;decelerate&#8221; in 2026, even though the analyst&#8217;s forecasts remain higher than consensus, albeit no longer the most optimistic among peers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/04/44643100/us-stocks-likely-to-open-lower-after-the-worst-selloff-since-2020-tariff-announcement-was-100-smoot-hawley-disguised-as-thoughtful-policy-says-expert" rel="noreferrer noopener">Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was &#8216;100% Smoot Hawley Disguised As Thoughtful Policy,&#8217; Says Expert</a>
Shanker&#8217;s earnings per share forecasts for Progressive stand at $18.35, $18.80 and $20.40 for 2025 through 2027, respectively — each representing a significant premium of 18% to 21% above current consensus estimates.
While acknowledging that it may seem counterintuitive to consider a downgrade under such optimistic projections, the analyst indicated that there are underlying reasons that justify a more cautious stance.
The analyst pointed out that Progressive has achieved a 15% compound annual growth rate in revenue over the past decade through 2024, primarily through organic means, with minimal changes to its share count. The company&#8217;s small acquisitions, such as ARX and Protective, were completed using cash rather than equity.
Additionally, operating earnings per share have grown at a 22% annual rate over the same period, well above the typical growth seen across the insurance sector.
The analyst acknowledged tariffs might negatively impact margins more than anticipated, similar to how inflation in used cars and parts during 2021–2022 drove up loss costs for auto insurers.
Shanker does not see this as a major factor in valuing Progressive.
Emphasizing the cyclical nature of the business, the analyst suggested that while periods of over- and under-earning are inevitable, the long-term growth trajectory remains the most important consideration.
PGR Price Action: Progressive shares closed down 10.23% at $257.64 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44623855/billionaire-investor-ray-dalio-warns-of-abrupt-unconventional-changes-in-markets-heres-how-the-tariff-machine-aff" target="_blank" rel="noreferrer noopener">Ray Dalio Warns Of ‘Abrupt, Unconventional Changes&#8217; In Markets: Here&#8217;s How The ‘Tariff Machine&#8217; Affects Currency, Monetary And Fiscal Policies</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Equities

News

Downgrades

Markets

Analyst Ratings

Movers

Trading Ideas

General

Cyclical Ceiling In Sight? BofA Turns Cautious On Progressive During Macro Shifts

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 5 years by 4.94% on an annualized basis producing an average annual return of 18.7%. Currently, PTC has a market capitalization of $16.82 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 5 years ago, it would be worth $234.55 today based on a price of $139.77 for PTC at the time of writing.
<h3>PTC's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743799509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In PTC 5 Years Ago Would Be Worth Today

BofA Securities analyst Craig Siegenthaler revised estimates and price forecasts for several broker <a href="https://www.benzinga.com/topic/broker" target="_blank" rel="noreferrer noopener">stocks ahead of earnings season</a>.
The analyst writes that a deeper equity market correction poses EPS risks from cash sweep revenues, trading/margin loans, and AUM-based fees.
Siegenthaler expects further NNA slowdowns, especially in higher ROCA retail channel vs. wealth manager, projecting a modest dip in March.
Since the correction happened late in the quarter, most risks will surface in the second quarter instead of the first quarter of 2025, adds the analyst.
Charles Schwab: The analyst projects Charles Schwab Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) NII to keep rising, regardless of market or rates, as it pays down its costly FHLB/CD borrowings.
He sees a third consecutive quarter of net new asset growth, with a 4.7% estimate, near the low end of the company&#8217;s 5%-7% target.
The analyst reiterated the Underperform rating on the company and lowered the <a target="_blank" href="https://www.benzinga.com/quote/schw/analyst-ratings" rel="noreferrer noopener">price forecast from $74 to $66</a>.
Also, Siegenthaler revised EPS estimates for first-quarter FY25 to $1.03 (from $1.01), 2026 to $4.27 (from $4.82) and 2027 to $4.73 (from $5.26) due to the negative impact of a reduced interest rate forecast and lower AUM-based fees.
Meanwhile, the analyst maintains a long-term bullish stance on retail brokers, particularly online brokers like Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) and Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), as their valuations and ownership setups have improved post-correction year-to-date.
Siegenthaler continues to view online brokerage as a global secular trend, benefiting from its high-tech, low-cost model, which reaches mass customers at low price points and capitalizes on the demographic shift to digital.
Overall, the analyst maintains the Buy rating on LPL Financial Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>), thanks to strong <a href="https://www.benzinga.com/quote/lpla/analyst-ratings" target="_blank" rel="noreferrer noopener">organic growth and stable ROCA</a>.
Interactive Brokers Group: The analyst reduced the Interactive Brokers Group stock&#8217;s price <a href="https://www.benzinga.com/quote/ibkr/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from $307 to $265</a>.
Siegenthaler forecasts a 3% quarter-over-quarter revenue increase driven by higher trading volumes, with account growth expected to accelerate to 32%.
The analyst lowered first-quarter/2026/2027 EPS estimates to $1.99/$8.90/$10.62, from $2/$10.14/$12.27, respectively due to expectations of lower client engagement and the impact of lower short-term interest rates on net interest income.
Coinbase: Meanwhile, the analyst notes the strong trading levels Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) in the fourth quarter of 2024 were tough to replicate in the first quarter of FY25, with a decline in crypto prices slowing client activity.
As a result, the analyst lowered Coinbase's 2026/27 EPS estimates by over 10% and reduced the price forecast from $311 to $217.
Robinhood Markets: The analyst lowered the stock price <a href="https://www.benzinga.com/quote/hood/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $65 to $58</a>.
While Siegenthaler expects Robinhood&#8217;s revenues to rise 44% year-over-year, this still represents a 12% quarter-over-quarter decline due to lower trading.
At Robinhood, the analyst also anticipates higher expenses and a return to a normal 21% tax rate after previously being at 0% or lower since its 2021 listing.
The analyst revised the first-quarter FY25/2026/2027 EPS estimates to 29 cents/$1.49/$1.94, from 43 cents/$1.76/$2.18, respectively, due to a lower interest rate forecast, decelerating trading volumes, higher G&amp;A expenses, and a return to a normal tax rate.
Meanwhile, the analyst remains optimistic about the company&#8217;s long-term growth, driven by business expansion, new product launches, strong client relationships, and market growth both globally (including Singapore) and domestically.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44614042/jpmorgan-wells-fargo-morgan-stanley-bny-mellon-will-strike-a-cautious-tone-analysts" target="_blank" rel="noreferrer noopener">JPMorgan, Wells Fargo, Morgan Stanley, BNY Mellon Will &#8216;Strike A Cautious Tone&#8217;: Analysts</a></li>
</ul>
Photo: Shutterstock

Large Cap

Mid Cap

Price Target

Personal Finance

COIN

HOOD

IBKR

LPLA

SCHW

BofA Analyst Forecasts Slower Growth For Broker Stocks As Market Volatility Increases

ALMS

SLRN

Alumis and ACELYRIN File Joint Definitive Proxy Statement For Proposed Merger; Boards Unanimously Recommend Stockholders Vote "For" The Merger

On March 31, 2025, Atara Biotherapeutics, Inc., (the "Company") entered into an Amendment (the "Amendment") to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the "Agreement") with Pierre Fabre Medicament ("Pierre Fabre"). Under the terms of the Amendment, as of March 31, 2025, the Company has completed the transfer of all manufacturing responsibility to Pierre Fabre and Pierre Fabre will be, at its cost, responsible for manufacturing and supplying tabelecleucel for development and commercialization worldwide. Pierre Fabre has also agreed to assume the costs related to remediation of the third-party manufacturing facility to address the U.S. Food and Drug Administration's (the "FDA") requests to support resubmission of the BLA for tab-cel.
In exchange for accelerating the transfer of all manufacturing responsibility and assumption of such remediation costs by Pierre Fabre, among other things, the Company agreed to reduce the amount of certain potential future regulatory and commercial milestone payments under the Agreement. The Amendment did not change any of the royalties the Company is eligible to receive under the Agreement. Pursuant to the Amendment, the Company is now entitled to receive an aggregate of up to $550.0 million in additional potential milestone payments upon achieving certain regulatory and commercial milestones relating to tab-cel, including up to $40.0 million in potential regulatory milestones in connection with the approval by the FDA of a BLA for tab-cel under the terms of the Agreement (as amended by the Amendment).

Contracts

ATRA

Atara Biotherapeutics Transfers Full Manufacturing Responsibility For Tabelecleucel To Pierre Fabre; Now Entitled To Receive Up To $550M In Additional Potential Milestone Payments Upon Achieving Certain Regulatory And Commercial Milestones Relating To Tab-cel, Including Up To $40M In Potential Regulatory Milestones In Connection With The Approval By The FDA Of A BLA For Tab-cel

VZLA

Vizsla Silver Corp. Pauses Field Of Work At Panuco Project Out Of Abundance Of Caution Due to Security Conditions In The Area

NOVA

Sunnova Received NYSE Noncompliance Notice

CHGG

Chegg Received NYSE Noncompliance Notice

Guidance

DOCN

DigitalOcean Holdings Reaffirms Guidance For Fiscal Quarter Ended March 31, 2025 And Year Ended Dec 31, 2025

RILY

B. Riley Financial Receives Delinquency Notice From Nasdaq Indicating Co. Is Not In Compliance As A Result Of Delayed 10-K Filling

The stock market took a dive, but <a href="https://www.benzinga.com/news/25/03/44132684/cathie-woods-bold-move-8-straight-days-of-buying-beam-therapeutics-as-stock-soars-14">Cathie Wood</a> didn&#8217;t flinch. Instead of retreating, the Ark Invest CEO saw an opportunity and went on a buying spree. According to<a href="https://www.investors.com/news/cathie-wood-ark-invest-coinbase-stock-robinhood-tesla-palantir-amd-coin-hood-tsla-pltr/"> Investor&#8217;s Business Daily</a>, her firm snapped up shares of Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), and more on March 10.
<h2 class="wp-block-heading">Big Bets in a Turbulent Market</h2>
Investor&#8217;s Business Daily said that Ark Invest picked up 79,318 shares of Tesla, valued at $17.62 million based on Monday&#8217;s closing price of $222.15. The firm also acquired 269,864 shares of Robinhood for $9.6 million and 64,358 shares of Coinbase, worth $11.53 million.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Other buys included 147,551 shares of Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) for $14.26 million, 152,253 shares of Palantir at $11.63 million, and 485,005 shares of Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), valued at $12.46 million.
It&#8217;s a familiar strategy for Wood, who has built a reputation for &#8220;buying the dip.&#8221; She firmly believes in disruptive innovation and has placed some of her biggest bets on Tesla.&nbsp;
Wood thinks part of the recent demand dip for Tesla could result from broader fears about the economy. In a recent<a href="https://www.ark-funds.com/webinars/mar-2025-fund-webinar?utm_medium=email&amp;_hsmi=353364069&amp;utm_content=353364069&amp;utm_source=hs_email"> Ark Invest webinar</a>, she said, &#8220;Now, clearly, the political dynamics of the last few months are hitting demand; we also would suggest that the economic outlook is hitting demand—not just for Tesla—but for all auto manufacturers.&#8221;&nbsp;
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Despite the stock&#8217;s 31% decline this year and a growing list of challenges, Wood has maintained a bullish outlook. She told <a href="https://www.bloomberg.com/news/articles/2025-03-25/cathie-wood-sticks-with-tesla-predicts-stock-will-hit-2-600">Bloomberg TV</a> that Tesla&#8217;s price could soar over the next five years.
Tesla has been at the center of controversy for months. Since Elon Musk&#8217;s closer ties with the Trump administration, the electric vehicle company has faced public protests, boycotts, and even vandalism.&nbsp;
Musk&#8217;s role as an advisor to the Department of Government Efficiency has drawn criticism, with some accusing the CEO of shifting the company into politically charged territory.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
The turmoil has had financial consequences. Tesla&#8217;s stock has been on a downward trend, while competitors, particularly China&#8217;s BYD, have continued to gain market share. According to <a href="https://edition.cnn.com/2025/03/20/business/even-used-teslas-are-falling-out-of-favor/index.html">CNN</a>, Tesla vehicles&#8217; resale value has also dropped over the past month.
Amid the backlash, President Donald Trump publicly backed Musk. He said on <a href="https://truthsocial.com/@realDonaldTrump/posts/114141854575248527">Truth Social </a>that he would buy a Tesla, calling it a &#8220;show of confidence&#8221; in the company. The move follows a broader effort by Trump&#8217;s administration to support Tesla.&nbsp;
Commerce Secretary Howard Lutnick, the commerce secretary, encouraged Americans to invest in the company.&nbsp;
&#8220;I think if you want to learn something on this show tonight, buy <a href="https://www.benzinga.com/news/25/03/44209579/unprecedented-slide-tesla-sales-plummet-45-in-europe-as-musks-net-worth-dives-5-2b-in-a-week">Tesla</a>. It&#8217;s unbelievable that this guy&#8217;s stock is this cheap. It&#8217;ll never be this cheap again,&#8221; ​he told Fox News on March 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

BEAM

PLTR

TSLA

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'

Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) has outperformed the market over the past 20 years by 21.74% on an annualized basis producing an average annual return of 29.25%. Currently, Booking Holdings has a market capitalization of $140.58 billion. 
Buying $1000 In BKNG: If an investor had bought $1000 of BKNG stock 20 years ago, it would be worth $162,212.04 today based on a price of $4284.02 for BKNG at the time of writing.
<h3>Booking Holdings's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743798613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BKNG

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 30.62% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 29.43% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 25.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 16.95% at $0.41</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 10.71% at $4.80</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.41% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 6.82% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 5.87% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 5.41% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FLOOF">Flower One Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FLOOF#OTC">FLOOF</a>) shares closed down 90.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 30.31% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 30.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 22.60% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 16.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 15.09% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 10.41% at $0.52</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 10.11% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 9.26% at $0.77</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 9.01% at $3.23</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 8.95% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 8.63% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 8.16% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 7.25% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 6.92% at $1.05</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 6.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 5.89% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 5.82% at $5.02</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 5.68% at $0.95</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 5.41% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.94% at $0.59</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed down 4.62% at $141.95</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed down 4.49% at $1.71</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.46% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 4.44% at $0.59</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.23% at $1.37</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 4.09% at $0.39</li>
<li><a href="https://www.benzinga.com/quote/EHC">Encompass Health</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) shares closed down 3.84% at $97.96</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.70% at $8.60</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 3.29% at $51.41</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BBRRF

CARA

CBDY

CLSH

CNBX

CNTMF

CPHRF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

CWBHF

CXXIF

ELLXF

FLOOF

FUAPF

GTBIF

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MGWFF

NWVCF

OILFF

RMHB

RSSFF

SNDL

TCNNF

TGIFF

TLRY

UGRO

XXII

ZDPY

Marijuana Stock Movers For April 4, 2025

This week, the <a href="https://www.benzinga.com/topic/cannabis-industry">cannabis industry</a> saw a flurry of activity, from strategic mergers and robust financial reports to product launches and key regulatory developments.
Major players are repositioning themselves through acquisitions and leadership transitions while innovative products and partnerships are driving growth in consumer markets. Meanwhile, legal and policy debates continue to shape the future of cannabis regulation both domestically and abroad.
Here's a comprehensive roundup of the top news shaping the cannabis landscape.
<h2 class="wp-block-heading">Corporate Moves And Financial Results</h2>
Organigram Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) made headlines with its acquisition of Collective Project Limited for an upfront C$6.2 million, with additional contingent payments that could bring the total consideration up to C$24 million. The deal marks Organigram's first commercial entry into the fast-growing hemp‑derived THC beverage market in the U.S. and accelerates its move into Canada's emerging cannabis beverage category. CEO Beena Goldenberg explained, "The acquisition of Collective Project marks yet another strategic milestone towards Organigram's global leadership ambitions."
Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) announced an optional early prepayment on its senior secured term loan—settling $100 million at a discounted price of $97.5 million. CFO Judy Hong stated, "Canopy has further improved its balance sheet with this early prepayment by reducing our overall debt position as well as lowering annual interest costs." This transaction ensures that the company has no material debt until September 2027.
Grown Rogue International Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>) reported strong fourth‑quarter and full‑year 2024 results with revenue increasing 16% to $27.0 million and adjusted EBITDA rising 27% compared to the previous period. The company, which received licensing approval in New Jersey and expanded its Michigan operations, sees continued growth in competitive markets despite pricing pressures. CEO Obie Strickler emphasized the team's relentless focus on cost controls and yield improvements.
AYR Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTCQX">AYRWF</a>) announced a leadership transition with Steven M. Cohen stepping down as Interim CEO and Scott Davido taking over the role. "We appreciate Steven's willingness to stay on as an advisor as we continue to execute on our strategic initiatives," said Chairman Louis Karger. Cohen added, "I have appreciated the opportunity to lead AYR over the past few months and I do so with the utmost confidence that AYR is in the right hands."
Other significant updates include:
<ul>
<li>MediPharm Labs Corp. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/MEDIF#OTCQB">MEDIF</a>) posted a robust 2024 with net revenue up 27% to $42 million and gross profit improving to $12.8 million. The company also achieved an 81% improvement in its adjusted EBITDA loss.</li>
<li>IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported a 25% increase in Q4 revenue, a return to profit on adjusted EBITDA and robust performance driven by accelerated growth in its German operations.</li>
<li>Chicago Atlantic BDC, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>), formerly Silver Spike Investment Corp., delivered its first earnings report after completing a strategic acquisition of a diversified loan portfolio, with net investment income of $8.0 million and a NAV per share of $13.20.</li>
<li>Innocan Pharma Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/INNPF#OTC">INNPF</a>) revealed that its full‑year 2024 revenues surged by 114.6% to US$29.4 million, while its gross profit increased by 118.6% to US$26.2 million.</li>
<li>Jones Soda Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSDA#NASDAQ">JSDA</a>) reported Q4 revenue falling to $2.8 million and a net loss of $4.6 million, driven by a $1.2 million inventory write‑off and declining sales volumes.</li>
<li>Rubicon Organics Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ROMJF#OTCQX">ROMJF</a>) celebrated record high net revenue of $48.7 million in 2024, achieving an adjusted EBITDA gain of $4.0 million and securing a $10 million credit facility to support expansion plans.</li>
</ul>
<h2 class="wp-block-heading">Product Launches And Brand Expansions</h2>
Consumer offerings continue to expand in Illinois. Grön (The Mother of All Edibles), founded by Christine Apple, launched its cannabis‑infused edibles—including Sugar‑Coated Pearls, MEGAs and Chocolate Mini Bars—exclusively at Curaleaf dispensaries beginning in April 2025. "We are thrilled to finally bring our products to the millions of cannabis consumers in Illinois," said Apple.
Meanwhile, MariMed Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#CSE">MRMD</a>, OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTCQX">MRMD</a>) introduced its Nature's Heritage line, featuring premium cannabis flower, pre‑rolls and vapes. The launch follows the opening of its Mt. Vernon, Illinois cultivation facility and marks the brand's debut in the state, with products now available in approximately 82% of Illinois dispensaries.
<h2 class="wp-block-heading">Legal, Regulatory And Policy Developments</h2>
Recent legal and regulatory developments continue to drive debate. In regulatory news, the U.S. Supreme Court sided with a trucker who was fired after testing positive for THC—allegedly after consuming a hemp‑derived CBD product. The decision, reported by <a href="https://www.marijuanamoment.net/supreme-court-sides-with-trucker-who-was-fired-over-thc-test-following-use-of-cbd-product/" target="_blank" rel="noopener">Marijuana Moment</a>, allows the trucker to seek triple damages under a federal anti‑racketeering law.
On the policy front, extensive analysis of the federal cannabis rescheduling debate reveals that moving cannabis from Schedule I to Schedule III would offer only modest benefits while leaving longstanding racial disparities and federal–state conflicts unresolved. A <a href="https://www.yalelawjournal.org/forum/decriminalizing-cannabis?utm_source=www.cultivated.news&amp;utm_medium=newsletter&amp;utm_campaign=states-that-will-lead-legal-weed-according-to-an-economist&amp;_bhlid=785740b498442d4fe25a0f0dc08d20cf6613e6d3" target="_blank" rel="noopener">Yale Law Journal forum article</a> argues for decriminalization and deregulation instead of rescheduling.
<h2 class="wp-block-heading">Federal Policy And Administration Developments</h2>
A recent article by <a href="https://www.marijuanamoment.net/marijuana-rescheduling-isnt-on-the-white-houses-new-list-of-top-drug-policy-priorities-under-the-trump-administration/" target="_blank" rel="noopener">Marijuana Moment</a> highlights that cannabis rescheduling is not among the Trump administration's top drug policy priorities. Instead, the administration is focusing on combating drug trafficking and the opioid crisis. While Trump had previously voiced support for cannabis rescheduling and medical cannabis legalization during his 2024 campaign, his current policy priorities emphasize enforcement against substances such as fentanyl, methamphetamines and heroin. This shift underscores the challenges and federal-state conflicts that continue to shape cannabis policy in the U.S.
<h2 class="wp-block-heading">Industry Challenges And Financial Distress</h2>
The sector continues to face significant financial challenges. A recent <a href="https://www.benzinga.com/markets/cannabis/25/03/44572746/cannabis-defaults-are-piling-up-3-companies-just-missed-payments-whos-at-risk-next" target="_blank" rel="noopener">Benzinga article</a> details defaults on key real estate leases by Gold Flora Corp., 4Front Ventures Corp. and TILT Holdings Inc. These defaults—driven by escalating liabilities-to-market cap ratios and high operating costs—signal a broader liquidity crisis that could threaten other operators such as Cannabist Holdings, Ascend Wellness Holdings and AYR Wellness.
<h2 class="wp-block-heading">The Bob Fireman Award</h2>
Nominations for the 2025 Bob Fireman Award for Entrepreneurship are now open. The award honors cannabis leaders who embody the legacy of Robert &#8220;Bob&#8221; Fireman—co-founder and former CEO of MariMed Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTCQX">MRMD</a>). With a submission deadline of May 1, 2025 and the winner to be announced live at the Benzinga Cannabis Capital Conference in Chicago from June 8–10, 2025, this accolade recognizes leaders committed to integrity, leadership and community impact. For more details, visit <a href="https://www.benzinga.com/markets/cannabis/25/04/44594542/know-a-cannabis-leader-who-stands-out-nominations-now-open-for-bob-fireman-award-by-benzinga" target="_blank" rel="noopener">this link</a>.
<h2 class="wp-block-heading">Interviews And Profiles</h2>
This week's exclusive interviews include:
<ul>
<li>"When Viral Icon Doug The Pug Got Sick, His Family Created A Cannabis Brand: ‘CBD Offers Real Benefits For Pets'" – an in‑depth look at Nonipup's innovative approach to pet wellness. <a href="https://www.benzinga.com/markets/cannabis/25/04/39798184/when-viral-icon-doug-the-pug-got-sick-his-family-created-a-cannabis-brand-cbd-offers-real-benefi" target="_blank" rel="noopener">Read the interview</a></li>
<li>"We've Accepted Mommy-Wine Culture; Why Not Cannabis?—Meet The Woman Behind The Largest Weed PR Firm In North America" – a profile of Rosie Mattio and her trailblazing work in cannabis public relations. <a href="https://www.benzinga.com/markets/cannabis/25/04/42205176/weve-accepted-mommy-wine-culture-why-not-cannabis-meet-the-woman-behind-the-largest-weed-pr-firm" target="_blank" rel="noopener">Read the profile</a></li>
<li>"Gary Payton Wants You To Rethink Cannabis: &#8216;It&#8217;s About Mental Health… It Brought My Mom Back In Her Final Days&#8217;" – an interview capturing Gary Payton's personal journey and his venture into cannabis wellness. <a href="https://www.benzinga.com/markets/cannabis/25/04/42205205/gary-payton-wants-you-to-rethink-cannabis-its-about-mental-health-it-brought-my-mom-back-in-her-" target="_blank" rel="noopener">Read the interview</a></li>
</ul>
<h2 class="wp-block-heading">Partnerships, Fintech And Banking Solutions</h2>
In fintech, Spendr, a Cincinnati‑based cannabis payments startup, raised over $2.7 million in fresh capital as it prepares to expand ahead of a planned Series A later this year. Founder Lucas Gould noted that the funds came largely from existing individual investors, setting the stage for significant growth in 2025.
In banking news, Safe Harbor Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) is expanding its partnership with Würk—the leading Human Capital Management firm in the cannabis space. Through a mutual referral program, the two companies aim to bridge the gap between workforce management and financial services, addressing the industry's persistent challenge of accessing compliant banking solutions.
<h2 class="wp-block-heading">International Developments</h2>
Overseas, France has finally unveiled its full medical cannabis blueprint after a four‑year campaign. The new framework, which includes provisions for single‑use cannabis flower dosages to be consumed via CE‑certified dry herb vaporisation devices, represents a significant step forward for one of Europe's largest medical cannabis markets.
CEO Benjamin Alexandre‑Jeanroy of Augur Associates explained, "We're just waiting for what I call ‘bureaucratic suspense' to finalise and then the government will sign the decrees once they've been signed off by the EU." The framework also extends patient access until at least March 31, 2026.
<h2 class="wp-block-heading">Cannabis Accessories And Infused Products</h2>
In product innovation, Weedgets announced that its award‑winning Maze‑X and X5 One‑Hitter pipes are now available across Canada. CEO Michael Barenboym stated, "We&#8217;re thrilled to bring the Maze‑X and X5 pipes to Canada. Canada's market is the perfect fit for our award‑winning hardware."
In Michigan, Gelato Canna Co. launched its elevated cannabis‑infused confections—Dubai Bites and High From Dubai Chocolate Bar—which offer a unique twist on traditional treats. Both products retail for approximately $25 and are timed perfectly for 4/20 and Easter.
Finally, Wynk expanded its beverage portfolio with the launch of new 10mg THC Lemonade Seltzers, available in Lemonade, Strawberry Lemonade and Raspberry Lemonade. CEO Angus Rittenburg explained, "We created our 10mg Lemonade Seltzers to meet the growing demand for higher‑dose options—without losing what makes Wynk special." The seltzers are now available online in 37 states and at retail locations across 18 states.
<h2 class="wp-block-heading">UFA Partnership With Trulieve</h2>
In sports and wellness news, the Ultimate Frisbee Association (UFA) has named Trulieve an official partner for 2025. This marks one of the first partnerships between a professional team sports league in North America and a multi‑state cannabis operator. League CEO and Commissioner Tim DeByl stated, "The world of health and wellness for athletes has evolved and Trulieve has become a leader in enhancing lives through cannabis." The partnership will see Trulieve's brand featured throughout the UFA season, including digital content and in‑venue education.
<h2 class="wp-block-heading">See You Next Week</h2>
From strategic acquisitions and robust financial results to innovative product launches and pivotal regulatory shifts, this week has encapsulated the dynamism and complexity of the cannabis industry. With major players repositioning themselves and new consumer products making their debut, the sector continues to evolve at a rapid pace.
As legal and policy debates persist alongside expanding market opportunities both domestically and internationally, the industry remains poised for further transformation. We'll continue to monitor these dynamic trends and keep you updated.
Want more in-depth analysis and up-to-the-minute updates on the cannabis industry? Subscribe to our newsletter for real‑time insights and more in‑depth analysis.
See you next week!

Earnings

Government

Regulations

AAWH

AYRWF

CSE:MRMD

GRAM

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

IIPR

IMCC

INNO

INNPF

JSDA

LIEN

MEDIF

MRMD

ROMJF

SHF Holdings, Inc. - Class A Common Stock

SHFS

TLLTF

WEED

This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

<a href="https://www.bloomberg.com/news/articles/2025-04-04/meta-wisconsin-data-center-to-cost-nearly-1-billion" title="https://www.bloomberg.com/news/articles/2025-04-04/meta-wisconsin-data-center-to-cost-nearly-1-billion">https://www.bloomberg.com/news/articles/2025-04-04/meta-wisconsin-data-center-to-cost-nearly-1-billion</a>

'Meta Plans Nearly $1 Billion Data Center Project In Wisconsin' - Bloomberg

Global markets plunged in the first week of the new quarter after President Donald Trump announced sweeping new tariffs on Wednesday—an event <a href="https://www.benzinga.com/25/04/44616760/donald-trump-sets-reciprocal-tariffs-on-key-trade-partners-in-historic-policy-shock">he dubbed "Liberation Day."</a>
Trump unveiled a set of retaliatory tariffs with differentiated rates depending on the trading partner. The announcement sparked backlash from analysts, who criticized the methodology and raised fears of retaliation <a href="https://www.benzinga.com/25/04/44647999/trumps-tariff-war-could-take-us-tech-industry-back-a-decade-while-china-steam-rolls-ahead-analyst-says">from global trade partners.</a>
China, the country with which the U.S. has the largest trade deficit, was hit with a steep 34% tariff, prompting Beijing to respond with similar countermeasures by the end of the week. The escalation marked the beginning of a new global trade war between the world's two largest economies.
Other key trading partners were also targeted: the European Union faced a 20% tariff, Japan 24%, and India 26%. Canada and Mexico were spared, as long as their exports complied with USMCA provisions.
The surprise severity of the measures sent shockwaves through markets, surpassing even the most pessimistic forecasts. <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645518/strong-jobs-report-offers-hope-but-will-it-be-enough-to-counter-tariff-turmoil">A strong March jobs report</a> offered little reassurance to investors, who remain focused on the looming economic fallout from rising tariffs.
<h3 class="wp-block-heading">Trillions Of Wealth Evaporates As Stocks Crash </h3>
Trillions of dollars in market value were wiped <a href="https://www.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">out from Wall Street</a>. 
The S&amp;P 500 Index recorded its worst weekly decline since March 2020, when markets were devastated by the onset of COVID-19 lockdowns.
With the S&amp;P 500 plunging 10.5% over Thursday and Friday, this marks only the fourth time such a sharp two-day drawdown has occurred in modern market history—joining October 1987, September 2008, March 2020, and now April 2025.
The Nasdaq 100 plunged more than 20% from its February all-time high, officially <a href="https://www.benzinga.com/government/regulations/25/04/44647678/nasdaq-100-enters-bear-market-dow-in-correction-territory-as-traders-anxiously-await-powell-remarks">entering bear market territory.</a>
Mega-cap tech stocks led the rout, with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) posting its worst two-day drop since October 2008. 
Financial stocks also suffered steep losses, with double-digit declines across JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and others.
Oil prices bore the brunt of the sell-off. Crude dropped 10% on the week, hitting a four-year low, pressured by weakening demand expectations and a surprise announcement from OPEC+. The cartel disclosed plans for a larger-than-expected production hike starting in May, raising fears of an oversupply in global energy markets.
On Friday, Federal Reserve Chair Jerome Powell failed to soothe market concerns, reiterating "no hurry" on interest rate cuts and highlighting that the new <a href="https://www.benzinga.com/government/regulations/25/04/44648681/powell-cites-tariff-driven-inflation-risks-shrugs-off-trumps-call-for-perfect-time-to-cut-rates">tariffs could fuel inflation.</a>
Meanwhile, Trump continued to publicly pressure the central bank, stating that now is the "perfect time" to lower interest rates.
Also on Friday, Treasury Secretary Scott Bessent defended the tariff plan, attributing the roots of the market collapse instead to China's DeepSeek AI breakthrough.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44652055/its-more-a-mag-seven-problem-than-a-maga-one-treasury-secretary-says-as-wall-street-meltdowns">&#8216;It&#8217;s More A Mag 7 Problem Than A MAGA One,&#8217; Says Bessent As Wall Street Implodes</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Federal Reserve

ETFs

AAPL

Trump Tariffs Trigger Wall Street Bloodbath, S&P 500 Notches Worst Weekly Drop Since 2020: This Week In Markets

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

ALNY

AMGN

BIIB

GILD

REGN

VRTX

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

To <a href="https://www.benzinga.com/markets/25/03/44533852/what-would-buffett-do-with-markets-inches-away-from-the-extreme-fear-zone-is-it-finally-time-to-be-greedy">paraphrase</a> legendary investor Warren Buffett, a market participant should acquire shares of good companies that find themselves in temporarily bad circumstances. 
Under this framework, consumer technology giant Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) ought to rank as a tremendous buying opportunity amid the Wall Street bloodbath. Long-term data suggests that it is indeed an opportunity — but as a trader, timing matters.
Following the close of the midweek session, President Donald Trump announced <a href="https://www.benzinga.com/25/04/44613907/tariff-shock-incoming-as-trump-prepares-sweeping-trade-duties-what-traders-need-to-know">sweeping new trade tariffs</a>, an event he termed "Liberation Day." The initiative is a symbolic push to tackle the ballooning U.S. trade deficit <a href="https://www.benzinga.com/topic/tariffs">with major global partners</a>. Unfortunately, the levies were steeper than analysts expected, <a href="https://www.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">sending shockwaves through global markets</a> on Thursday.
Even as the Street digested the news and the broader implications, one day of extreme volatility wasn't enough, with Friday being subjected to another crimson tide. Prominent <a href="https://www.benzinga.com/general/market-summary/25/04/44643100/us-stocks-likely-to-open-lower-after-the-worst-selloff-since-2020-tariff-announcement-was-100-smoot-hawley-disguised-as-thoughtful-policy-says-expert">experts voiced their displeasure</a> at the tariffs, warning about severe consequences stemming from decelerated economic activity.
Still, amid the social media uproar, there was one point that stood out. Creative Planning Chief Market Strategist Charlie Bilello remarked that while the VIX or the so-called fear index reached its highest closing level since August 2024, the S&amp;P 500 has historically delivered "higher than average" returns following significant surges in volatility.
Since Apple stock is a benchmark security — leveraging a tremendous influence on both the tech ecosystem and the wider equities space — it stands to reason that its present volatility is a long-term buying opportunity. After all, one wouldn't naturally expect a giant like Apple to be permanently deflated.
From a patient investor's perspective, the red ink serves as a potential time machine — a chance to hop on the train that was previously missed. But from a trader's perspective, diving into Applr stock now may not be the most prudent decision.
<h1 class="wp-block-heading">The Death Cross in AAPL Stock is Warning First, Then Opportunity</h1>
To be sure, opportunistic traders will find it difficult to avoid reacting greedily to the hemorrhaging. Adding to the contrarian fervor, Apple stock is on the absolute cusp of printing the dreaded <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44629335/apple-stock-slammed-by-trump-tariffs-is-a-death-cross-next">death cross</a> — a technical sign when a security's 50-day moving average crosses below its 200 DMA.
On paper, the death cross represents a warning, marking the beginning of a serious downcycle or even an outright bear market. For many investors, it may symbolize the last chance to exit shares or take protective measures through advanced options strategies before further volatility erupts.
On the other hand, there's also the contrarian thought process that when the death cross flashes, much (if not most) of the bad news has already been baked in. Therefore, it's possible, if not likely, that the technical indicator could be a buying signal.
Here's the thing about Apple stock: while its death cross statistically represents a compelling buying opportunity, in the near term, the indicator should be interpreted at face value.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-1024x576.jpg" alt="" class="wp-image-858378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
More specifically, over the past decade, Apple stock printed five death crosses. Sure enough, three months to one year removed from this negative intersection, Apple has swung higher across these time intervals four out of five times (or 80%). However, at the one-month mark following the death cross, Apple has only risen one time — meaning that the failure rate pops to 80%.
From a statistical wide angle, it's difficult to analyze how Apple stock will respond given that extreme volatility is rare. Right now, the equity is on the verge of losing about 12% in the trailing five sessions. The last time Apple lost double-digit percentage points in a one-week period was in April 2016.
Pulling up a historical chart, one can see that the volatile event that took place a decade ago took several months to recover. And that's the lesson the death cross is broadcasting: yes, it is a buying opportunity but not right now.
<h1 class="wp-block-heading">Switch Hitting for the Agnostic Trader</h1>
Being a successful trader requires not being married to a specific direction and that's the opportunity available in Apple stock. With the current flashing of the death cross likely to result in near-term volatility, aggressive traders may first want to consider the 195/190 bear put spread for the options chain expiring May 2.
The above transaction involves buying the $195 put (at a time-of-writing ask of $1,225) and simultaneously selling the $190 put (at a bid of $970). Subsequently, the proceeds from the short put partially offset the debit paid for the long put, resulting in a net cash outlay of $255.
Should Apple fall to or below the short strike price at expiration, the maximum reward is the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $245 (a payout of 96%). This trade plays off the fact that the average one-month loss (assuming only the negative scenario) following the death cross is 1.06%.
For long-side traders, patience may be required. One compelling idea that stands out is the 215/220 bull call spread for the options chain expiring July 18. This trade plays on the rebound effect of the death cross while also respecting the time component. Executing this trade requires buying the $215 call and simultaneously selling the $220 call, with the aim that Apple will hit this latter price at expiration.

Photo: Shutterstock

Options

Tech

Options Corner: Apple Flashs Contrarian Death Cross — But Wait For The Right Count

<h2>Maxeon Provides Strategic Business Update</h2>
PRNewswire
SINGAPORE, April 4, 2025 /PRNewswire/ -- Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>), a global leader in solar innovation and channels, today provided an update on key business issues, recent transactions, and transformation initiatives.
"Maxeon continues to transform its business to compete more effectively in a challenging solar market, and delivering top-tier solar panels and renewable energy solutions to our customers for the long-term remains our highest priority," said George Guo, Maxeon CEO. "While the Company still faces near-term headwinds, we are making progress in strengthening our supply chain versatility and resilience, streamlining operations, increasing efficiency, and reducing cost. We are confident in the future of solar energy and in Maxeon's ability to best meet the needs of our growing U.S. partner and IPP network."
Maxeon focuses its energy on the U.S. solar market Maxeon has successfully concluded the previously announced transactions to strategically restructure its business portfolio and geographic market focus to concentrate exclusively on the U.S. market, where its presence and planned onshore manufacturing can create a strong platform to drive growth and success for the Company and its expanding network of partners.
As previously disclosed, Maxeon has sold certain non-U.S. assets, with proceeds to Maxeon's balance sheet of approximately $94 million dollars. These restructuring transactions have positioned Maxeon for the future, ensuring a clear focus on U.S. residential, commercial, and utility power plant markets.
&nbsp;

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon Solar Technologies Provides Strategic Business Update; Focuses On U.S. Market, Completes $94M Non-U.S. Asset Sale, And Restructures Business To Strengthen Supply Chain And Drive Growth In Residential, Commercial, And Utility Solar Sectors

Management

EDSA

Edesa Biotech Appoints Peter Weiler As CFO; Succeeds Stephen Lemieux

Press Releases

Vital Energy Announces Conversion of 2.0% Cumulative Mandatorily Convertible Series A Preferred Stock

Vital Energy Schedules Second-Quarter 2024 Earnings Release and Conference Call

Vital Energy to Expand Delaware Basin Position Through Bolt-on Acquisition

Vital Energy Reports Second-Quarter 2024 Financial and Operating Results

Point Energy Partners II Completes $1.1 Billion Sale to Vital Energy

Vital Energy Schedules Third-Quarter 2024 Earnings Release and Conference Call

Vital Energy Reports Third-Quarter 2024 Financial and Operating Results

Vital Energy Provides Details for its Fourth-Quarter 2024 Earnings Release and Conference Call

Vital Energy Reports Fourth-Quarter and Full-Year 2024 Financial and Operating Results

Vital Energy Provides Details for its First-Quarter 2025 Earnings Release and Conference Call

VTLE

Berry Corp

Crescent Energy Company Class A Common Stock

Crescent Energy

Dorchester Minerals, L.P. - Common Units Representing Limited Partnership Interests

Comments

Vital Energy

Noticias

Últimas noticias sobre Vital Energy (NYSE:VTLE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL